Press Release: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Ad hoc announcement pursuant to Art.
Ad hoc announcement pursuant to Art. 53 LR Cenerimod 4 mg showed clinically meaningful improvement in the mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect
GNW: Idorsia to advance cenerimod into Phase 3 development for treatment of | Newsticker fuw.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fuw.ch Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 11, 2021Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as
(1)
Ad hoc announcement pursuant to Art. 53 LR
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS. This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Japan, Australia or South Africa
Idorsia launches the offering of approx. CHF 600 million convertible bonds
Allschwil, Switzerland -
1
Idorsia Ltd (SIX: IDIA, Idorsia ) today announced the launch of approx. CHF 600 million senior unsecured convertible bonds (the Bonds ) due 2028 convertible into shares of Idorsia (the Shares ). The net proceeds from the offering will be used to support commercial product launches in several key markets in 2022 (pending regulatory approval) and to fund the further development of the company s advancing late-stage pipeline (https://www.idorsia.com/about-ido